(Q45301057)

11 December 2017

Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up (English)

1 reference

11 December 2017

0 references

1 reference

11

1 reference

11 December 2017

9

Claudia Schoch

1 reference

11 December 2017

Tanja Lahaye

1

1 reference

11 December 2017

Birte Riehm

2

1 reference

11 December 2017

Ute Berger

3

1 reference

11 December 2017

Peter Paschka

4

1 reference

11 December 2017

Martin C Müller

5

1 reference

11 December 2017

Sebastian Kreil

6

1 reference

11 December 2017

Kirsten Merx

7

1 reference

11 December 2017

Uwe Schwindel

8

1 reference

11 December 2017

Rüdiger Hehlmann

10

1 reference

11 December 2017

language of work or name

English

0 references

publication date

1 April 2005

1 reference

11 December 2017

1 reference

11 December 2017

103

1 reference

11 December 2017

1659-1669

1 reference

11 December 2017

8

1 reference

Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia

11 December 2017

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20922

Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20922

Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20922

A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20922

Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20922

High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20922

Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20922

Comparison of chromosome banding analysis, interphase- and hypermetaphase-FISH, qualitative and quantitative PCR for diagnosis and for follow-up in chronic myeloid leukemia: a study on 350 cases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20922

Molecular monitoring of response to imatinib (Glivec) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous remission

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20922

Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20922

Dynamics of BCR-ABL mRNA expression in first-line therapy of chronic myelogenous leukemia patients with imatinib or interferon alpha/ara-C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20922

Prognostic factors for patients with chronic myeloid leukaemia in chronic phase treated with imatinib mesylate after failure of interferon alfa

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20922

Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia after failure of interferon-alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20922

Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase: comparison with historic data

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20922

Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic responders

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20922

The significance of myelosuppression during therapy with imatinib mesylate in patients with chronic myelogenous leukemia in chronic phase

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20922

Testing the prognostic model of Marin et al in an independent chronic myelogenous leukemia study group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20922

A randomized study of interferon-alpha versus interferon-alpha and low-dose arabinosyl cytosine in chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20922

In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20922

Results of a prospective phase 2 study combining imatinib mesylate and cytarabine for the treatment of Philadelphia-positive patients with chronic myelogenous leukemia in chronic phase

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20922

Emergence of clonal cytogenetic abnormalities in Ph- cells in some CML patients in cytogenetic remission to imatinib but restoration of polyclonal hematopoiesis in the majority

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20922

Clonal Ph-negative hematopoiesis in CML after therapy with imatinib mesylate is frequently characterized by trisomy 8.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20922

Chromosomal abnormalities in Philadelphia chromosome-negative metaphases appearing during imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20922

Imatinib and beyond--the new CML study IV. A randomized controlled comparison of imatinib vs imatinib/interferon-alpha vs imatinib/low-dose AraC vs imatinib after interferon-alpha failure in newly diagnosed chronic phase chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20922

The German competence network ‘Acute and chronic leukemias’

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20922

Accurate and rapid analysis of residual disease in patients with CML using specific fluorescent hybridization probes for real time quantitative RT-PCR

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20922

Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. French Chronic Myeloid Leukemia Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20922

inferred from DOI database lookup

7 January 2021

based on heuristic

Trisomy 8 in Philadelphia chromosome (Ph1)-negative cells in the course of Ph1-positive chronic myelocytic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20922

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1002/CNCR.20922

1 reference

11 December 2017

1 reference